NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results

Mon, 31 Aug 2026 07:33:00 -0400

TORONTO and HAIFA, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, is pleased to announce its financial results for the second quarter ended June 30, 2026 (“Q2”), and to provide a corporate update on its recent activities and upcoming milestones.

The Company’s full set of unaudited condensed interim consolidated financial statements for the six months ended June 30, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at

NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results

Mon, 31 Aug 2026 07:33:00 -0400

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 28 Aug 2026 16:01:00 -0400

TORONTO and HAIFA, Israel, Aug. 28, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced that it is scheduled to participate in the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9–10, 2026, in New York City.

Yoram Drucker, Co-Founder, Chairman and Vice President of Strategic Development of NurExone, will deliver an investor presentation and participate in scheduled one-on-one meetings with investors. “As NurExone continues its preclinical development activities and preparations for potential

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 28 Aug 2026 16:01:00 -0400

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 28 Aug 2026 16:01:00 -0400

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 28 Aug 2026 16:01:00 -0400

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 28 Aug 2026 16:01:00 -0400

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 28 Aug 2026 16:01:00 -0400

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 28 Aug 2026 16:01:00 -0400

NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Fri, 28 Aug 2026 16:01:00 -0400

Form D NurExone Biologic Inc.

Fri, 21 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26958013.html

Form D NurExone Biologic Inc.

Fri, 21 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26958013.html

Form D NurExone Biologic Inc.

Fri, 21 Aug 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260821/26958013.html

NurExone names David Stolick to board, hires investor firm

Tue, 28 Jul 2026 17:24:32 -0400

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) has appointed David Stolick to its board of directors, effective July 28, 2026, according to a company statement. Stolick succeeds the late James "Jay" Richardson.

Stolick previously served as VP of Finance at V-Wave Ltd., a U.S.-Israeli medical device company acquired by Johnson & Johnson in October 2024. He has also held the roles of CFO at Exalenz Bioscience and BrainStorm Cell Therapeutics, and Corporate Controller at M-Systems. He holds a B.A. in Economics and Accounting from Ben-Gurion University and is a Certified Public Accountant.